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Abstract
Improved versions of inositol-1,4,5-trisphosphate (InsP3) sensors were created to follow in-
tracellular InsP3 changes in single living cells and in cell populations. Similar to previous
InsP3 sensors the new sensors are based on the ligand binding domain of the human type-I
InsP3 receptor (InsP3R-LBD), but contain a mutation of either R265K or R269K to lower
their InsP3 binding affinity. Tagging the InsP3R-LBD with N-terminal Cerulean and C-termi-
nal Venus allowed measurement of InsP3 in single-cell FRET experiments. Replacing Ceru-
lean with a Luciferase enzyme allowed experiments in multi-cell format by measuring the
change in the BRET signal upon stimulation. These sensors faithfully followed the agonist-
induced increase in InsP3 concentration in HEK 293T cells expressing the Gq-coupled AT1
angiotensin receptor detecting a response to agonist concentration as low as 10 pmol/L.
Compared to the wild type InsP3 sensor, the mutant sensors showed an improved off-rate,
enabling a more rapid and complete return of the signal to the resting value of InsP3 after
termination of M3 muscarinic receptor stimulation by atropine. For parallel measurements
of intracellular InsP3 and Ca
2+ levels in BRET experiments, the Cameleon D3 Ca2+ sensor
was modified by replacing its CFP with luciferase. In these experiments depletion of plasma
membrane PtdIns(4,5)P2 resulted in the fall of InsP3 level, followed by the decrease of the
Ca2+-signal evoked by the stimulation of the AT1 receptor. In contrast, when type-III PI 4-ki-
nases were inhibited with a high concentration of wortmannin or a more specific inhibitor,
A1, the decrease of the Ca2+-signal preceded the fall of InsP3 level indicating an InsP3-, in-
dependent, direct regulation of capacitative Ca2+ influx by plasma membrane inositol lipids.
Taken together, our results indicate that the improved InsP3 sensor can be used to monitor
both the increase and decrease of InsP3 levels in live cells suitable for high-throughput
BRET applications.
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Introduction
Inositol-1,4,5-trisphosphate (InsP3) plays a central role in calcium signaling. Its production is
catalyzed by phospholipase C enzymes activated through receptor stimulation. Measurements
of InsP3 kinetics for a long time relied upon isotope labeling of cell populations followed by ex-
traction and HPLC-separation of the active (1,4,5) isomer from the inactive (1,3,4) one [1].
Mass measurements of InsP3 using radio-receptor assays have also been used [2] to measure
absolute mass changes, again from populations of cell, but these methods have been quite cum-
bersome and unable to provide very detailed time resolution. Moreover, these methods did not
allow detection of kinetic changes in single cells with accurate comparisons with other parame-
ters, such as cytoplasmic Ca2+ changes. These deficiencies prompted several groups, including
ours, to develop InsP3 sensor that would be useful for single-cell analysis. With the advent of
fluorescent proteins and the development of fluorescence resonance energy transfer (FRET)
technology, InsP3 probes based on the ligand binding domain of the InsP3 receptor have been
introduced and used successfully in several single-cell applications [3–7].
In reviewing our experimental data obtained with a sensor that was developed in our group
(using the same principles referenced above) and comparing it with published sensors, such as
IRIS [3], we noted that the sensors not only distorted InsP3 kinetics because of their buffering
effects (a complication that is unavoidable with any probe), but they also showed InsP3 kinetics
suggestive of slow off-rates. To overcome this problem, we designed modified probes to address
these kinetic deficiencies. Importantly, we also wanted to take this tool further such that it
could be used in cell populations allowing a format amenable to screening applications.
Here we report on the fine-tuning and characterization of our InsP3 sensor based on the
human type-I InsP3 receptor LBD (residues 224–605). Structural studies showed that InsP3
binding leads to a conformational change of this protein domain, which can be translated to a
change in FRET signal between two appropriate fluorophores placed at the two ends of the
LBD. Similar probes have been introduced and published (see Table 1). It has been show earlier
that deletion of the N-terminal 223 amino acids increases the affinity of the LBD, so the 224–
605 LBD has a higher affinity than the native InsP3 receptor channel [8]. Therefore, we decided
to engineer slightly lower affinity mutants by mutating the InsP3 binding site in order to im-
prove its off-rate upon decrease in InsP3 but still keep their abilities to detect the increase of
InsP3 level. In addition, we have demonstrated the ability of these probes to faithfully monitor
InsP3 concentrations by either FRET or bioluminescence resonance energy transfer applica-
tions (BRET).
To analyze and compare our sensors, we needed an experimental system in which an in-
crease or decrease in InsP3 concentration could be equally established. For this, type-1 angio-
tensin receptor (AT1R) or the M3 cholinergic receptor was transiently transfected into HEK
293T cells, so that InsP3 concentration could be increased by angiotensin II or carbachol stimu-
lation, respectively. Decrease of InsP3 was evoked by terminating the muscarinic response by
atropine. Under these conditions both the wild-type and the mutant sensors were able to show
the rapid rise in InsP3 levels, but the mutants were able to detect a more rapid and full decline
in InsP3 concentration. Our data suggest that these improved mutant sensors are suitable to in-
vestigate InsP3 signaling more accurately than previous ones either by single-cell imaging or in
cell population measurements.
Measurement of IP3
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Materials and Methods
Materials
Molecular biology reagents were obtained from Fermentas (Vilnius, Lithuania). Cell culture
dishes and plates were purchased from Greiner (Kremsmunster, Austria). Coelenterazine h
was purchased from Regis Technologies (Morton Grove, IL). Lipofectamine 2000 was from
Invitrogen (Carlsbad, CA). Rapamycin was obtained fromMerck (Darmstadt, Germany). Gen-
eCellin transfection reagent was from BioCellChallenge (Toulon, France). Atropine was pur-
chased from EGIS (Budapest, Hungary). Unless otherwise stated, all other chemicals and
reagents were purchased from Sigma (St Louis, MO).
DNA constructs
The R265K, R269K, R568K, R504K and R265,269K mutations were introduced by site-directed
mutagenesis (Agilent Technologies, Santa Clara, CA USA) in the previously created
mRFP-InsP3R-LBD (residues 224–605 of human type-1 InsP3 receptor S1+) construct used for
bacterial expression of the fusion proteins [9]. To create the InsP3 sensors first we made a
FRET plasmid backbone by cloning the monomeric Venus [10] into the pEYFP-C1 plasmid, in
which YFP was already replaced by Cerulean [11], using EcoRI and NotI enzymes. The wild
type or mutant InsP3R-LBDs were then inserted between the two fluorophores using XhoI and
Table 1. InsP3 sensors in use for single-cell fluorescent energy transfer-based applications.
Sensor InsP3-binding domain KD Fluorescent proteins Reference
LIBRA rat type-III InsP3R (1–604) 404 nM CFP/YFP [4, 31]
LIBRA-ΔN* rat type-III InsP3R (227–604) ND CFP/YFP [4, 5, 31]
LIBRA-vI rat type-I InsP3R (1–604) 269 nM CFP/Venus [32]
LIBRA-vII rat type-II InsP3R (1–604) 234 nM CFP/Venus [32]
LIBRA-vIIS LIBRAvII R440Q 117 nM CFP/Venus [32]
LIBRA-vIII rat type-III InsP3R (1–604) 492 nM CFP/Venus [5, 32]
LIBRA-vIIIS LIBRAvIII R440Q  250 nM CFP/Venus [32]
Fretino human type-I InsP3R (224–579) 8 nM CFP/YFP [7]
Fretino-2 Fretino R504Q 190 nM CFP/YFP [7]
Fretino-3** Fretino R508Q ND CFP/YFP [7]
Fretino-4 human type-I InsP3R (1–604) ND CFP/YFP [7]
IRIS-1 mouse type-I InsP3R (224–575) 549 nM (cell lysate), 437 nM (purified) Venus/CFP [3]
IRIS-1-Dmut** IRIS-1 T276A, K508Q ND [3]
IRIS-1.2 IRIS-1 K249Q 3–4 μM [3]
mouse type-I InsP3R (224–579) 95 nM Venus/CFP [3]
mouse type-I InsP3R (224–584) 105 nM Venus/CFP [3]
mouse type-I InsP3R (224–604) 107 nM Venus/CFP [3]
FIRE-1 rat type-I InsP3R (1–589) 31 nM CFP/YFP [6]
FIRE-2 rat type-II InsP3R (1–604) ND CFP/YFP [6]
FIRE-3 rat type-III InsP3R (1–604) 36 nM CFP/YFP [6]
KD values represent the InsP3 concentrations required to reach 50% of the dynamic range of the appropriate sensor. ND means not determined.
*InsP3 insensitive mutant of LIBRA
**non-binding mutant for control experiments
doi:10.1371/journal.pone.0125601.t001
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EcoRI resulting in two short linkers before and after the LBD (NEQRSR and NS). From these
FRET sensors the BRET sensors were prepared by replacing Cerulean with super Renilla lucif-
erase [12]. To improve the optical parameters, another set of BRET sensors were created by re-
placing Venus with the Venus cp173-Venus tandem used in other sensors like the Epac cAMP
sensor [13].
The Ca2+ sensor used in the BRET measurements was created by replacing the InsP3R-LBD
with the appropriate sequence derived from Cameleon D3 [14]. For the replacement, first this
sequence was amplified using PCR with the sense primer CTCGAGACCAACTGACAGAA
GAGCAGATTGCAGAG and antisense primer GAATTCAGTGCCCCGGAGCTGGAGA
TCTTC, and then it was cloned into the BRET plasmid using XhoI and EcoRI enzymes.
Wild type human M3 cholinergic receptor (N-terminal 3x-hemagglutinin tagged) was pur-
chased from S&T cDNA Resource Center (Rolla, MO). The non-internalizing rat type-I angio-
tensin receptor (AT1R-Δ319) was described earlier [15]. The plasma membrane targeted FRB-
mRFP and mRFP-FKBP-5-ptase constructs used for rapamycin-induced PtdIns(4,5)P2 deple-
tion were described earlier [16] with the difference that for plasma membrane targeting of the
FRB protein, we used the N-terminal targeting sequence (1–10) of mouse Lck (GenBank acces-
sion number: NM_001162433) [17].
Cell culture
HEK 293T and COS-7 cells (ATCC, Manassas, VA) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Lonza 12–604) supplemented with 10% fetal bovine serum, 50 U/ml
penicillin and 50 μg/ml streptomycin in a 5% humidified CO2 incubator at 37°C in 10 cm tissue
culture plastic dishes.
InsP3 binding experiments
mRFP-tagged wild type and mutant InsP3R-LBD domains, built into the pET-23b bacterial ex-
pression vector (Novagen) were used to transform the BL-21 DE3 Star strain of Escherichia coli
(Invitrogen). Bacterial cells were grown to A600 0.6–0.9 at 37°C and induced with 300 μM iso-
propyl-1-thio-β-D-galactopyranoside at 18–20°C for 8 hours. Purification of the recombinant
protein as well as InsP3 binding assay were performed as described previously [9], using
0.75 μCi (1 nM) [3H]Ins(1,4,5)P3 (Amersham Biosciences) and 200 ng protein in an incubation
volume of 50 μl.
Fluorescence Resonance Energy Transfer (FRET) measurements
For FRET measurements HEK 293T cells were trypsinized and plated on poly-lysine-pre-
treated (0.001%, 1 hour) No 1.5 glass coverslips in 35 mm plastic dishes at 3x105 cells/dish den-
sity. After one day the culture medium was changed to 1 ml Opti-MEM (Gibco) medium, and
then 200 μl transfection solution containing the indicated DNA constructs (1 μg total DNA/
dish) and 2 μl/dish Lipofectamine 2000 was added. After 6 hours 1 ml DMEM containing
serum and antibiotics was added. Measurements were performed 24–32 hours after the trans-
fection. Before the measurements the coverslips were placed into Attofluor cell chambers (Invi-
trogen) and the medium was changed to 800 μl of a modified Krebs–Ringer buffer containing
120 mMNaCl, 4.7 mM KCl, 1.2 mM CaCl2, 0.7 mMMgSO4, 10 mM glucose, and 10 mMNa-
HEPES, pH 7.4. Measurements were performed at room temperature using an inverted micro-
scope (Axio Observer D1, Zeiss, Germany) equipped with a 40x/1.3 oil-immersion objective
(Plan-APO, Zeiss) and a Cascade II camera (Photometrics, Tucson, AZ). Excitation wave-
lengths (435 nm and 500 nm) were set by a monochromator connected to a 75 W Xenon lamp
(DeltaRAM, Photon Technology International, Birmingham, NJ). The emitted light was
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separated by a dichroic beamsplitter (Chroma 69008bs), and then detected through the appro-
priate emission filters for Cerulean (470/24 nm) and Venus (535/30 nm). Images were acquired
every 5 s. The indicated reagents were also dissolved in modified Krebs–Ringer buffer and were
added manually in 200 μl, and mixed three times. The MetaFluor (Molecular Devices, Down-
ingtown, PA) software was used for data acquisition, whereas for further data analysis includ-
ing background subtraction, bleed through correction and 535/470 emission ratio calculation
the MetaMorph (Molecular Devices) software was applied.
Bioluminescence Resonance Energy Transfer (BRET) measurements
For BRET measurements HEK 293T cells were trypsinized and plated on poly-lysine-pre-
treated (0.001%, 1 hour) white 96-well plates at a density of 105 cells/well together with the in-
dicated DNA constructs (0.24–0.3 μg total DNA/well) and the cell transfection reagent (0.5 μl/
well Lipofectamine 2000 or 1.5 μl/well GeneCellin). After 6 hours 100 μl/well DMEM contain-
ing serum and antibiotics was added. Measurements were performed 24–27 h after transfec-
tion. Before measurements the medium of cells was changed to a medium (50 μl) containing
120 mMNaCl, 4.7 mM KCl, 1.2 mM CaCl2, 0.7 mMMgSO4, 10 mM glucose, and 10 mMNa-
HEPES, pH 7.4. Measurements were performed at 37°C using a Mithras LB 940 multilabel
reader (Berthold, Germany). The measurements started with the addition of the cell permeable
luciferase substrate, coelenterazine h (40 μl, final concentration of 5 μM), and counts were re-
corded using 485 and 530 nm emission filters. Detection time was 500 ms for each wavelength.
The indicated reagents were also dissolved in modified Krebs–Ringer buffer and were added
manually in 10 μl. For this, plates were unloaded, which resulted in an interruption in the re-
cordings. All measurements were done in triplicates. BRET ratios were calculated by dividing
the 530 nm and 485 nm intensities, and normalized to the baseline.
Confocal microscopy
COS-7 cells were cultured on IBIDI μ-Slide 8 Well dishes (IBIDI GmbH, Cat. No.: 80826;
2x104 cells/well) and transfected with the indicated constructs (1 μg DNA total/dish) using
0.5 μl/well Lipofectamine 2000 for 24 h. Confocal measurements were performed at 35°C in a
modified Krebs-Ringer buffer described above, using a Zeiss LSM 710 scanning confocal mi-
croscope and a 63x/1.4 oil-immersion objective. Post-acquisition picture analysis was per-
formed using the Photoshop (Adobe) software to expand to the full dynamic range but only
linear changes were allowed.
Statistical analysis
To calculate the half-time values (τ) of the decay phase, a curve fitting procedure was applied
to the values in each individual experiment using the 3 parametric exponential decay equation
of (y = y0+ae
-bx). τ values were then averaged and subjected to a t-test.
Results
Generation of reduced affinity InsP3 sensors that can be used in energy
transfer measurements
To design an improved InsP3 sensor first we decided to perform a moderate modification in
the InsP3 binding domain (224–605 amino acids) of human type-I InsP3 receptor (IP3R-LBD)
[18] by replacing specific arginine residues to lysines. Since the side chain of lysine is shorter
than that of arginine and lysine is a less basic amino-acid than arginine (pI-values are 9.74 and
10.76, respectively) we reasoned that interaction of the mutant protein with negatively charged
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phosphate groups of InsP3 will be weaker. We expected that this manipulation would decrease
the binding affinity and therefore increase the off-rate performance of the sensor. Based on the
crystal structure of the binding domain [19] we selected R265, R269, R504 and R568 residues
for mutation (Fig 1A). To investigate the InsP3 binding properties of these proteins, first we
created constructs for bacterial expression. The mRFP-, and 6xHis-tagged InsP3 binding do-
mains were purified on Ni2+ columns, and in vitro binding assays were performed using [3H]
InsP3 as the tracer. As shown in Fig 1B the binding of R265K, R269K and R568K were weaker
compared to the wild type protein, while the R504K and the double mutant R265,269K were
very poor InsP3 binders. Scatchard analysis of the curves also showed the lower affinity of the
mutants: the KD value for the R265K, R269K and R568K mutants were 6.06 nM, 10.07 nM and
5.30 nM, respectively compared to 3.04 nM for the wild type LBD. Based on these results, the
R265K and R269K mutants were selected for further analysis.
In previous studies we created the InsP3R-LBD with various N-terminal fluorescent tags,
such as mRFP or Cerulean, in combination with a C-terminal Venus tag. Application of the
protein as InsP3 sensor in BRET measurements requires that the N-terminal fluorescent pro-
tein tag be replaced with a luciferase enzyme. Fig 1C shows the final structure of the InsP3 sen-
sors that contain either Cerulean [11] or Super Luciferase (Sluc) [12] tag on their N-terminus,
and Venus on the C-terminus. Studies on the dependence of energy transfer efficiency between
fluorescent proteins suggested that introduction of double-acceptor moieties may significantly
enhance the FRET efficiency value [13]. Therefore, we also created constructs with tandem yel-
low fluorescent tag (cp173 Venus and Venus) on their C-termini [13].
As shown before for the previously developed sensors, expression of these sensors in mam-
malian cells (COS-7 and HEK 293T) resulted in uniform cytoplasmic distribution of the fusion
proteins and their reduced levels in the nucleus (Fig 1D). Similarly to other published InsP3
sensors (see Table 1), InsP3 binding caused a decrease of energy transfer in both FRET and
BRET measurements (Fig 1E and 1F). Notably, duplication of the acceptor did not result in im-
provement of the signal in the BRET format (Fig 1F). Since raw BRET ratio values often show a
spontaneous increase over time, we included wells that were left unstimulated and used these
to correct for baseline drift. From these data the reciprocal of the I/I0 values were calculated
and plotted, therefore the elevation of cytoplasmic InsP3 level corresponds to an increased
value on the graphs. Since the BRET application is done in cell suspension and therefore inher-
ently reports on averaged cell responses, the subsequent characterization was done using the
BRET approach.
Characterization of the InsP3 sensitivity and reversibility of the reduced
affinity InsP3 sensors
To compare the InsP3-induced signals of the wild type and low affinity InsP3 sensors, HEK
293T cells were transfected with the cDNAs of both the human AT1 receptor and the Sluc/
Venus version of the appropriate InsP3 sensor. BRET changes were then recorded following
angiotensin II (Ang II) stimulation. As shown on Fig 2A, increasing concentrations of Ang II
from 10–12 to 10–7 M resulted in an increasing BRET signal in case of both the wild type and
the mutant sensors. The signals also showed a kinetic difference as the concentration of Ang II
was increased (Fig 2A). While the maximal response was the same, a moderate shift to the
right occurred on the dose-response curve in case of the sensor with the R265K mutation re-
flecting the lower affinity of this mutant sensor (Fig 2B).
To investigate the reversibility of the InsP3 binding of the sensors, HEK 293T cells transient-
ly expressing the M3 cholinergic receptor were stimulated first with carbachol (10 μM), which
activated the Gq signaling pathway and elevated the cytoplasmic InsP3 and Ca
2+ levels. These
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responses can be quickly terminated by adding the competitive antagonist atropine (10 μM).
As shown in Fig 3A the rising phases of the signals, which reflect the elevation of InsP3, were
indistinguishable between the wild-type and mutant InsP3 sensors (however, note the low tem-
poral resolution of about 3 points per minute). In contrast, the mutant sensor showed a signifi-
cantly enhanced off-rate (τ = 23.0±2.3 s) compared to the wild type sensor (τ = 44.9±7.5 s)
(Mean ± S.E.M. n = 5, p = 0.024), and a complete return to the baseline. InsP3 measurement
performed with the wild-type sensor revealed an elevated level of cytoplasmic InsP3 concentra-
tion after the atropine treatment, which may reflect an incomplete dissociation of InsP3 from
the high affinity wild-type sensor or a non-complete inhibition of M3R signaling with atropine.
Notably, in control cells, which were not treated with atropine, the InsP3 level remains elevated
up to 10 minutes consistent with a slow desensitization of the M3R, as demonstrated previously
[20].
Parallel measurements of cytoplasmic Ca2+ concentration, performed under the same ex-
perimental condition (in the same plate, but in cells that expressed the BRET version of a previ-
ously described low KD Ca
2+ sensor [14] instead of the InsP3 sensors), revealed the termination
of the Ca2+ signal upon atropine treatment with a kinetic, which was highly similar to the one
showed by the mutant InsP3 sensor (Fig 3B).
Parallel cytoplasmic InsP3 and Ca
2+ measurements suggest a role of
phosphoinositides in the generation of capacitative Ca2+ entry
Having performed these control experiments we wanted to apply these new sensors to address
some lingering questions in InsP3/Ca
2+ signaling. It has been widely accepted that a sustained
elevation in cytoplasmic Ca2+ upon stimulation with a Ca2+-mobilizing agonist is the conse-
quence of emptying the intracellular Ca2+ stores, with a sequential activation of Ca2+ influx
into the cells via the Ca2+ channel Orai1 [21]. However, the role of phosphoinositides has been
raised not only as the source of InsP3 but also as possible regulators of the capacitative Ca
2+
entry process [22].
To investigate the role of inositol phospholipids and InsP3 in this process, we performed
parallel measurements of cytoplasmic InsP3 and Ca
2+ levels under conditions, where either the
plasma membrane (PM) phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] level was rap-
idly reduced by the rapamycin-inducible PM PtdIns(4,5)P2-depletion system (Fig 4A) or the
PtdIns(4)P supply was decreased by wortmannin pretreatment (Fig 4D). To avoid the compli-
cating effects of receptor desensitization, HEK 293T cells expressing the rapamycin-regulated
phosphatase system were transfected with the cDNA of a C-terminally tail-deleted non-inter-
nalizing AT1 receptor mutant (AT1R-Δ319) [15]. As shown on Fig 4B, stimulation with Ang II
resulted in a large and sustained increase in cytoplasmic InsP3 levels, which was rapidly
Fig 1. Characterization of the newly developed InsP3 sensor. (A) Schematic drawing of the inositol 1,4,5-trisphosphate (InsP3)-binding core domain
based on its crystal structure [18]. Residues in the alpha helical domain and the beta-trefoil domain are highlighted in green and yellow, respectively. InsP3 is
highlighted in blue. The hinge region is shown in purple. Arginine to lysine mutations were introduced in the ligand binding residues at positions 265, 269, 504
and 568 (red arrows). (B) In vitro characterization of the inositol phosphate binding of recombinant mRFP-tagged InsP3 binding domains. The assays were
performed using [3H]InsP3 (see methods) in the presence of the indicated concentrations of the respective unlabeled ligand. Two separate experiments in
triplicates. (C) Schematic representations of domain structures of the different InsP3 biosensors and a modified Cameleon D3 BRET sensor for measuring
the changes in cytoplasmic Ca2+ concentration. The InsP3 sensors contain Cerulean (FRET) or Sluc (BRET) on the N-terminus, the ligand-binding domain of
the human type-I InsP3-receptor and either Venus or circularly permuted Venus (cp173) and Venus on the C-terminus. The blue lines show the approximate
location of the designed mutations (R265K). The Ca2+ sensor contains the MLCK calmodulin binding peptide M13 and the D3 variant of calmodulin. (D)
Representative images of InsP3 or Ca
2+ biosensor-containing COS-7 cells. (E) Measurements of FRET in individual HEK 293T cells expressing the FRET
InsP3 biosensor and the AT1 angiotensin receptor. InsP3 production of the cells was triggered by 1 μM angiotensin II (Ang II). Note that binding of InsP3
resulted in a decrease of the energy transfer. (F) Measurement of BRET in HEK 293T cells expressing two types of BRET InsP3 biosensors containing a
single or a tandem fluorescent protein (Venus or cp173-Venus and Venus). InsP3 production was induced by ionomycin (10 μM). The curves indicate the raw
BRET ratios of individual wells of a 96-well white tissue culture plate used in the BRETmeasurements.
doi:10.1371/journal.pone.0125601.g001
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terminated upon PtdIns(4,5)P2 depletion evoked by rapamycin addition. The decay of the
InsP3 signal correlated well with the decline of the cytoplasmic Ca
2+ level (Fig 4C) measured in
parallel (side by side on the same plate) using the BRET version of the original Cameleon D3
Ca2+ sensor [14]. This correlation indicates that the newly developed InsP3 sensor is suitable
for monitoring the rapid termination of this signaling event.
Next we compared InsP3 and Ca
2+ kinetics following Ang II stimulation of cells pretreated
with either 10 μMwortmannin or 10 nM A1, a recently published potent and more specific
PI4KIIIα inhibitor [23]. Wortmannin at this concentration inhibits type-III PI4Ks (both α and
β), thereby limiting the replenishment of the phosphoinositide pools [24]. As shown on Fig 4E,
Fig 2. Comparison of the activation properties of the wild type and low-affinity InsP3 sensors. (A) Normalized BRET ratio (reciprocal of I/I0) measured in
HEK 293T cells transiently transfected with the AT1 angiotensin receptor and the wild type or R265Kmutant InsP3 biosensors upon Ang II stimulation (10
-12-10-7 M)
addedmanually. To avoid desensitization of the receptor a non-internalizing receptor was used (AT1R-Δ319). Error bars show standard error values from three
independent measurements performed in triplicate. (B) Concentration-response curves for Ang II. InsP3 responses weremeasured 5minutes after stimulation. The
right shift caused by the R265Kmutation corresponds to the lower ligand binding affinity of the InsP3 biosensor.
doi:10.1371/journal.pone.0125601.g002
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Fig 3. Comparison of the reversibility of the wild type and low-affinity InsP3 sensors. (A) InsP3
production was evoked in HEK 293T cells expressing the M3 cholinergic receptor and various BRET InsP3
biosensors. Stimulation of the cells with 10 μM carbachol (Carb) added manually resulted in a maximal InsP3
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both the Ang II-evoked InsP3 and Ca
2+ responses became transient when cells were pretreated
with 10 nM A1 or 10 μMwortmannin for 10 minutes before Ang II stimulation, whereas the
initial increases were very similar. This is in agreement with the earlier observation using iso-
tope-based InsP3 measurements, in which wortmannin pretreatment greatly reduced resting
PtdIns(4)P but only slightly affected the prestimulatory PtdIns(4,5)P2 level [24]. However,
strikingly, the decay in InsP3 level was much slower than the decline in the Ca
2+ levels after the
pretreatment with PI4K inhibitors (Fig 4F). This suggested that the rapidly declining Ca2+ can-
not be simply caused by the depletion of PtdIns(4,5)P2 as a cause of declining InsP3 and refill-
ing of the endoplasmic reticulum (ER) Ca2+ stores. These results suggested that PI4K
inhibition had an additional effect on Ca2+ signals, most likely on entry via the store-operated
pathways.
Discussion
The purpose of the present studies was to develop an InsP3 sensor that allows kinetic measure-
ment of cytoplasmic InsP3 concentration both in singe cells and in cell populations. The con-
formational change evoked by InsP3 binding to the LBD domain of the InsP3 receptor served
as a rational basis for the development of various energy transfer-based InsP3 sensors, summa-
rized in Table 1. The evolution and evaluation of these sensors clearly showed that their InsP3
binding affinity is a crucial factor in their suitability. While using the high affinity wild-type
LBD domain in these applications makes the sensors very sensitive, their buffering effects and
their slow off-rate has limited their use, especially in experiments where assessment of InsP3
decreases was important. Several approaches have been used to modify the binding affinity of
the LBD. For example, keeping the N-terminal inhibitory domain or truncation of the C-termi-
nus of the LBD both reduced the binding affinity (Table 1). Mutations of amino acids responsi-
ble for the interaction with the InsP3 ligand can either increase or decrease the affinity of ligand
interaction. Unfortunately, the impact of such modifications often is too drastic and results in
unsuitable sensors. In our studies the starting point was the binding domain (amino acids 224–
605) of the human type-I InsP3 receptor, which we previously used as a cytoplasmic InsP3 buff-
er [25]. In vitro binding measurements performed with tritium-labelled InsP3 resulted in an
IC50 value of 4 nM for the ligand binding affinity of the GFP-tagged version of this domain [9],
which is in good agreement with the 3 nM, calculated here from the Scatchard analysis for the
ligand binding of the mRFP-tagged LBD. Since adding the N-terminal inhibitory domain led
to a large drop in binding affinity (about one order of magnitude) [25], we attempted to make a
more subtle change in the LBD, replacing key arginines within the InsP3 binding site with ly-
sines, trying to mimic the affinity close to that of the endogenous receptor. Among several mu-
tants tested, the R265K and R269K mutants has proven to be suitable candidates for the
development of improved InsP3 sensors.
For FRET applications the wild type, R265K and R269K mutant LBDs were tagged with mo-
nomeric versions of Cerulean and Venus on their N- and C-termini, respectively. To make the
sensor suitable for use in BRET measurements, we replaced Cerulean with Luciferase. The
response sustained for at least 10 minutes (upper graph) as indicated by both the wild type and the R265K
mutant InsP3 biosensors. To examine how the biosensors can monitor the decrease of the InsP3 signal the
activation process was stopped by 10 μM atropine (lower graph) added manually, which caused the
divergence of the curves corresponding to the wild type and R265Kmutant InsP3 biosensors. (B) Parallel
measurement of the cytoplasmic Ca2+ level measured with the modified Cameleon D3 BRET sensor.
Experiments were carried out on the same plate in parallel wells containing cells expressing the Ca2+ sensor
instead of the InsP3 sensors. Values are means ± SE of three independent experiments performed
in triplicate.
doi:10.1371/journal.pone.0125601.g003
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advantage of BRET measurement over FRET is that it can be carried out in simple plate readers
and that it shows the average change in a cell population. Since it does not require excitation,
there is no crosstalk between the emission channels. Therefore, energy transfer can be followed
by simply calculating the emission ratio without any correction. Data processing is reduced
only to taking the reciprocal of the ratio values to obtain an increase when InsP3 level elevates,
and normalizing the data to the resting values. Replacement of Venus with a double Venus
construct (Venus cp173-Venus) did not yield further benefits either in the FRET or BRET for-
mat. Our mutant InsP3 sensors tested in BRET applications showed a slightly reduced but still
high sensitivity to agonist stimulation, while they performed better when the decay of InsP3
was followed after termination of InsP3 production. This was either achieved by terminating
receptor stimulation or rapidly removing PtdIns(4,5)P2, the precursor of InsP3. This allowed us
to perform specific experiments to test the utility of these sensors to address questions regard-
ing the connection between InsP3 and Ca
2+ entry regulation.
It has been shown previously that pretreatment of cells with concentrations of wortmannin,
that inhibit PI3- and PI4-kinases, modifies the shape of the agonist-evoked Ca2+ signal by elim-
inating its sustained elevation [24, 26]. This was initially attributed to the fact that wortmannin
limits the replenishment of the plasma membrane phosphoinositide pools by inhibiting type-
III PI4Ks, therefore leading to the run-down of these lipids during agonist stimulation [24].
Since Ca2+ influx through the capacitative Ca2+ entry pathway is regulated by the ER luminal
Ca2+ concentration, which in turn, is controlled by the opening of the InsP3 receptor channels
in the ER, it was logical to assume that the falling InsP3 levels in wortmannin-treated cells
would allow ER Ca2+ pools to refill and shut down the store-operated Ca2+ entry process. In
fact, it has been shown by early studies that Icrac (the current that corresponds to store-regulat-
ed Ca2+ entry) is inhibited by wortmannin [27]. Subsequent studies performed after the identi-
fication of the molecules responsible for SOCE, have also indicated that phosphoinositides in
the plasma membrane may directly influence this Ca2+ entry route either by affecting the Orai
channels or the ER-sensor STIM1 molecule [22, 28–30].
Our new ability of monitoring InsP3 and Ca
2+ changes allowed us to address this question
in a way that relied upon endogenous levels of STIM1 and Orai1.
We compared the decay kinetics of Ca2+ and InsP3 either after rapidly removing PtdIns(4,5)
P2 or limiting phosphoinositide supplies by wortmannin (or now the more specific PI4KIIIa in-
hibitor, A1) pretreatment. We found a significant difference between the two manipulations:
while the InsP3 and Ca
2+ decreases were parallel after PtdIns(4,5)P2 depletion, the Ca
2+ de-
crease was substantially faster than that of InsP3 in the PI4K inhibitor pretreated cells. This
suggested that PI4KIIIa inhibition exerted an additional effect on Ca2+ signaling. that was dif-
ferent from a simple PtdIns(4,5)P2 depletion evoked by the PM-recruited 5-ptase.
The most important difference between the two manipulations is the change in the level of
plasma membrane PtdIns(4)P. While PtdIns(4,5)P2 elimination by the 5-ptase increases
PtdIns(4)P levels, A1 or wortmannin pretreatment selectively depletes PtdIns(4)P even before
Fig 4. Reduction of plasmamembrane PtdIns(4)P and PtdIns(4,5)P2 levels and their effect on the InsP3 and Ca2+ signals upon hormonal
stimulation. (A) Schematic representation of the plasmamembrane PtdIns(4,5)P2 depletion system [33]. Addition of rapamycin induces the
heterodimerization of the FRB and FKBP domains in PM-FRB and FKBP-5ptase and thus causes the translocation of the latter molecule to the plasma
membrane where it degrades PtdIns(4,5)P2. (B and C) HEK 293T cells were transiently transfected with AT1R-Δ319 together with the PtdIns(4,5)P2
depleting system and the indicated BRET sensors. After hormonal stimulation (100 nM Ang II), 300 nM rapamycin was added manually to cause acute
depletion of PtdIns(4,5)P2 in the PM. (means ± SE, n = 4). (D) During the synthesis of PtdIns(4,5)P2, first the PI4K enzymes phosphorylate PI, and then
PIP5K produces PtdIns(4,5)P2 from PtdIns(4)P. The plasmamembrane PtdIns(4)P content can be depleted by preincubation of the cells with the selective
PI4KIIIα inhibitor, A1 or a high concentration of wortmannin (Wm). (E and F) HEK 293T cells were transiently transfected with AT1R-Δ319 together with the
indicated BRET sensors. A 10-minute preincubation with 10 μMwortmannin or 10 nM A1 was used to decrease the PtdIns(4)P level of the PM. The curves
show the changes in the normalized BRET ratio (means ± SE, n = 3) of the indicated sensors upon manual addition of 100 nM Ang II.
doi:10.1371/journal.pone.0125601.g004
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agonist stimulation and PtdIns(4,5)P2 decreases only occur after agonist addition. All of these
argue for a role for PtdIns(4)P or a mechanism sensitive to its level in playing a role in the con-
trol of store-operated Ca2+ entry. These conclusions were consistent with those of earlier re-
ports using different approaches [22, 27].
We also observed a peculiar decrease of the Ca2+ levels below the prestimulatory values
when cells were stimulated after PI4K inhibition. While this may be a feature brought out by
our genetically encoded Ca2+ sensor, it raised the possibility that Ca2+ extrusion is also stimu-
lated by agonists and together with inhibition of Ca2+ entry due to the simultaneous elimina-
tion of both PtdIns(4)P and PtdIns(4,5)P2 manifests in a Ca
2+ decrease below basal. Further
exploration of this possibility, however, was beyond the scope of this study.
In summary, in this paper we described and characterized an improved InsP3 sensor which
is based on the ligand binding domain of human type-1 InsP3 receptor but contains the R265K
mutation. While this sensor maintains its sensitivity and can be used to monitor small increases
of cytoplasmic InsP3 concentration, it also has an improved off-rate to follow the decrease of
the InsP3 level. While the sensor also works in FRET applications, an important new feature
was its adaptation for BRET applications usable in plate readers to support high-throughput
measurement of cytoplasmic InsP3 in live cells alone, or in combination with measurements of
other signaling factors, such as cytoplasmic Ca2+ concentration.
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